This is great news. Although the study only had 28 subjects, the findings are pretty strong. The article has not been peer-reviewed, so we should be cautious ab

This is great news. Although the study only had 28 subjects, the findings are pretty strong. The article has not been peer-reviewed, so we should be cautious about these findings. This source [1] mentions some controversy about a claim in this article: "The virus uses angiotensin converting enzyme 2 (ACE2) as its main route into the host, but their claim that the viral spike protein – which binds ACE2 – can also interact with CD147 is controversial." [1] https://www.bioworld.com/articles/433822-genentech-moves-actemra-into-phase-iii-covid-19-trial https://www.bioworld.com/articles/433822-genentech-moves-act...